Physician profile
Sheetal A Varde
NPI 1861411159
$3,379.24
in general payments reported to CMS, 2019-2025
40 companies · $857 in 2025
The $857 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $445 · 2020: $89.62 · 2021: $134 · 2022: $402 · 2023: $668 · 2024: $783 · 2025: $857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,309.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $645.19 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $358.08 | 2022-2025 | Vraylar |
| Pfizer INC. | $274.31 | 2019-2025 | |
| Lilly USA, LLC | $265.44 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $258.59 | 2022-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $142.12 | 2019-2025 | Breztri, Farxiga, Fasenra |
| Exact Sciences Corporation | $134.39 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $128.42 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $122.35 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Amgen INC. | $91.61 | 2019-2025 | Repatha, Otezla, Repatha |
| Idorsia Pharmaceuticals US INC | $82.74 | 2022-2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $81.36 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.80 | 2022-2023 | Gattex, Vpriv |
| Vanda Pharmaceuticals INC. | $56.36 | 2025 | Fanapt |
| Sanofi Pasteur INC. | $55.19 | 2019-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheetal Varde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.